SOMAÍ CBD 100 Isolate Oil
Indication
‘-Chronic pain
-Anxiety
-Schizophrenia
-Other Indications as Clinically Justified
References
1. Therapeutic Goods Administration (TGA). “Guidance for the use of medicinal cannabis in the treatment of chronic non-cancer pain in Australia”. January 25, 2024. https://www.tga.gov.au/medicinal-cannabis-guidance-documents.
2.Bergamaschi MM, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-26.
Titration and dosing
THESE TITRATION MODELS SERVE AS AN EXAMPLE AND MUST BE ADAPTED TO EACH PATIENT
| Days | Morning dose (mL of oral solution) | Evening dose (mL of oral solution) | Total daily dose (mL of oral solution) | Total CBD daily dose (mg) |
| 1-2 | 0.25 | 0.25 | 0.5 | 50 |
| 3-4 | 0.5 | 0.5 | 1 | 100 |
| 5-6 | 0.75 | 0.75 | 1.5 | 150 |
| 7-8 | 1 | 1 | 2 | 200 |
| 9-10 | 1.5 | 1.5 | 3 | 300 |
The patient should take the minimum dose that provides effective symptom relief with tolerable side effects.
The titration should be conservative, done with increments of 2.5 mg THC every 2 days (or with increments of 1.25 mg THC for fragile patients).
The dosage protocol can be adjusted according to the patient’s profile. Increase dose as necessary and as tolerated, up to 15 mg of THC. Daily THC doses exceeding 20–30 mg may elevate the risk of adverse events or lead to the development of tolerance without improving efficacy.1 Maximum recommended daily THC dose: 40 mg.
*Ideally, the administration should start with an evening dose to limit adverse events and encourage the development of tolerance.
References
1. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. EwoRean Journal of Internal Medicine. 2018; 49: 12-19.
Terpenes and Minor Cannabinoids profile
Not applicable for this product